Al-Aly and his colleagues found that people starting the GLP-1 drugs had lower risks of developing addiction to multiple substances. Compared with the other medications, people taking the GLP-1 drugs ...
Demand for Wegovy and other GLP-1 drugs used to treat obesity and diabetes has skyrocketed, but a new report suggests that many people may not be sticking with their weight-loss treatment long enough.
The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...
A majority of people with overweight or obesity prescribed glucagon-like peptide 1 receptor agonists (GLP-1 RAs) discontinue them within 1 year, with higher quit rates among those without type 2 ...
A study suggests GLP-1 medications may reduce the risk of substance use disorders among patients with diabetes, indicating ...
GLP-1 drugs are meant to treat metabolic diseases like diabetes and obesity. But as they become more available, some people might choose to use them even if they're not currently overweight. NPR's ...
Getty Images The limited treatment options available for alcohol use disorder emphasize the urgent need for more research into pharmacologic therapies. While more research is needed, preclinical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results